Sangamo Therapeutics (SGMO) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$34.9 million.
- Sangamo Therapeutics' Net Income towards Common Stockholders fell 47218.97% to -$34.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.9 million, marking a year-over-year increase of 1999.46%. This contributed to the annual value of -$97.9 million for FY2024, which is 6201.35% up from last year.
- Latest data reveals that Sangamo Therapeutics reported Net Income towards Common Stockholders of -$34.9 million as of Q3 2025, which was down 47218.97% from -$20.0 million recorded in Q2 2025.
- Over the past 5 years, Sangamo Therapeutics' Net Income towards Common Stockholders peaked at $21.1 million during Q1 2023, and registered a low of -$114.5 million during Q2 2023.
- Over the past 5 years, Sangamo Therapeutics' median Net Income towards Common Stockholders value was -$44.0 million (recorded in 2022), while the average stood at -$42.8 million.
- In the last 5 years, Sangamo Therapeutics' Net Income towards Common Stockholders crashed by 306233.42% in 2021 and then skyrocketed by 14800.88% in 2023.
- Sangamo Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$37.5 million in 2021, then plummeted by 38.63% to -$51.9 million in 2022, then fell by 16.08% to -$60.3 million in 2023, then skyrocketed by 61.2% to -$23.4 million in 2024, then plummeted by 49.3% to -$34.9 million in 2025.
- Its Net Income towards Common Stockholders was -$34.9 million in Q3 2025, compared to -$20.0 million in Q2 2025 and -$30.6 million in Q1 2025.